27 research outputs found

    The site of synthesis of the iron-sulfur subunits of the flavoprotein and iron-protein fractions of human NADH dehydrogenase

    Get PDF
    The site of synthesis of the iron-sulfur subunits of the flavoprotein and iron-protein fractions of the human respiratory chain NADH dehydrogenase has been investigated to test the possibility that any of them is synthesized in mitochondria. For this purpose, antibodies specific for individual subunits of the bovine enzyme, which cross- reacted with the homologous human subunits in immunoblot assays, were tested against HeLa cell mitochondrial proteins labeled in vivo with [35S]methionine in the absence or presence of inhibitors of mitochondrial or cytoplasmic protein synthesis. The results clearly indicated that all the iron-sulfur subunits of the flavoprotein and iron-protein fractions of human complex I are synthesized in the cytosol and are, therefore, encoded in nuclear genes

    Parkinson's disease deficits in time perception to auditory as well as visual stimuli - A large online study

    Get PDF
    Cognitive deficits are common in Parkinson鈥檚 disease (PD) and range from mild cognitive impairment to dementia, often dramatically reducing quality of life. Physiological models have shown that attention and memory are predicated on the brain鈥檚 ability to process time. Perception has been shown to be increased or decreased by activation or deactivation of dopaminergic neurons respectively. Here we investigate differences in time perception between patients with PD and healthy controls. We have measured differences in sub-second- and second-time intervals. Sensitivity and error in perception as well as the response times are calculated. Additionally, we investigated intra-individual response variability and the effect of participant devices on both reaction time and sensitivity. Patients with PD have impaired sensitivity in discriminating between durations of both visual and auditory stimuli compared to healthy controls. Though initially designed as an in-person study, because of the pandemic the experiment was adapted into an online study. This adaptation provided a unique opportunity to enroll a larger number of international participants and use this study to evaluate the feasibility of future virtual studies focused on cognitive impairment. To our knowledge this is the only time perception study, focusing on PD, which measures the differences in perception using both auditory and visual stimuli. The cohort involved is the largest to date, comprising over 800 participants

    Prognostyczne znaczenie ujemnego wyniku echokardiograficznej pr贸by dobutaminowej w warunkach submaksymalnego obci膮偶enia - badanie z 3-letni膮 obserwacj膮

    Get PDF
    Wst臋p: Celem badania by艂a ocena warto艣ci predykcyjnej ujemnego wyniku echokardiograficznej pr贸by dobutaminowej w warunkach submaksymalnego obci膮偶enia (NsubDSE) w odniesieniu do wyst臋powania powa偶nych incydent贸w sercowych. Metody i wyniki: Analizie poddano pacjent贸w z ujemnym wynikiem echokardiograficznej pr贸by dobutaminowej nale偶膮cych do dw贸ch grup wyr贸偶nionych w zale偶no艣ci od przewidywanej maksymalnej cz臋sto艣ci rytmu serca (PMHR) (< 85% oraz &#8805; 85% PMHR), w kt贸rych oceniano wyst臋powanie powa偶nych niepo偶膮danych incydent贸w sercowych w ci膮gu 3 lat. Spo艣r贸d 756 pacjent贸w z ujemnym wynikiem echokardiograficznej pr贸by dobutaminowej u 415 chorych warto艣膰 PMHR wynios艂a 85% lub wi臋cej. W obu grupach stwierdzono podobny odsetek os贸b z frakcj膮 wyrzutow膮 powy偶ej 50% (80,6% vs. 81,9%; p = 0,66). Grupa z NsubDSE charakteryzowa艂a si臋 wi臋ksz膮 cz臋sto艣ci膮 stosowania lek贸w hamuj膮cych przewodzenie przez 艂膮cze przedsionkowo-komorowe (58,7% vs. 39,9%; p < 0,0001) oraz wi臋ksz膮 cz臋sto艣ci膮 wyst臋powania cukrzycy (38,7% vs. 27,6%; p = 0,001). Analiza Kaplana-Meiera nie wykaza艂a r贸偶nic prze偶ycia bez zgonu sercowego (98% vs. 98%; p = 0,88), zawa艂u serca niezako艅czonego zgonem (94% vs. 94%; p = 0,85) lub wszystkich powa偶nych incydent贸w sercowych (81% vs. 78%; p = 0,24). Czynnikami predykcyjnymi incydent贸w sercowych w analizie wielozmiennej by艂y cukrzyca i zachowana frakcja wyrzutowa (p = 0,005). Wnioski: W niniejszym badaniu osi膮gni臋cie NsubDSE wi膮za艂o si臋 z korzystnym rokowaniem. Uzyskiwano je cz臋艣ciej u chorych na cukrzyc臋, ale w tej grupie cz臋艣ciej wyst臋powa艂y te偶 incydenty sercowe pomimo zachowanej frakcji wyrzutowej. U os贸b z tej grupy du偶ego ryzyka wskazana jest wi臋c dalsza diagnostyka choroby wie艅cowej

    New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31

    Get PDF
    This report is a summary of \u27New Cancer Immunotherapy Agents in Development\u27 program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy

    Daksha: On Alert for High Energy Transients

    Full text link
    We present Daksha, a proposed high energy transients mission for the study of electromagnetic counterparts of gravitational wave sources, and gamma ray bursts. Daksha will comprise of two satellites in low earth equatorial orbits, on opposite sides of earth. Each satellite will carry three types of detectors to cover the entire sky in an energy range from 1 keV to >1 MeV. Any transients detected on-board will be announced publicly within minutes of discovery. All photon data will be downloaded in ground station passes to obtain source positions, spectra, and light curves. In addition, Daksha will address a wide range of science cases including monitoring X-ray pulsars, studies of magnetars, solar flares, searches for fast radio burst counterparts, routine monitoring of bright persistent high energy sources, terrestrial gamma-ray flashes, and probing primordial black hole abundances through lensing. In this paper, we discuss the technical capabilities of Daksha, while the detailed science case is discussed in a separate paper.Comment: 9 pages, 3 figures, 1 table. Additional information about the mission is available at https://www.dakshasat.in

    HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's Disease

    Get PDF
    Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to identify patients at increased risk for development of anti-drug antibodies would facilitate selection of therapy and use of preventative strategies.This article is freely available via Open Access. Click on Publisher URL to access the full-text

    Case Reports1.鈥傾 Late Presentation of Loeys-Dietz Syndrome: Beware of TGF尾 Receptor Mutations in Benign Joint Hypermobility

    Get PDF
    Background: Thoracic aortic aneurysms (TAA) and dissections are not uncommon causes of sudden death in young adults. Loeys-Dietz syndrome (LDS) is a rare, recently described, autosomal dominant, connective tissue disease characterized by aggressive arterial aneurysms, resulting from mutations in the transforming growth factor beta (TGF尾) receptor genes TGFBR1 and TGFBR2. Mean age at death is 26.1 years, most often due to aortic dissection. We report an unusually late presentation of LDS, diagnosed following elective surgery in a female with a long history of joint hypermobility. Methods: A 51-year-old Caucasian lady complained of chest pain and headache following a dural leak from spinal anaesthesia for an elective ankle arthroscopy. CT scan and echocardiography demonstrated a dilated aortic root and significant aortic regurgitation. MRA demonstrated aortic tortuosity, an infrarenal aortic aneurysm and aneurysms in the left renal and right internal mammary arteries. She underwent aortic root repair and aortic valve replacement. She had a background of long-standing joint pains secondary to hypermobility, easy bruising, unusual fracture susceptibility and mild bronchiectasis. She had one healthy child age 32, after which she suffered a uterine prolapse. Examination revealed mild Marfanoid features. Uvula, skin and ophthalmological examination was normal. Results: Fibrillin-1 testing for Marfan syndrome (MFS) was negative. Detection of a c.1270G > C (p.Gly424Arg) TGFBR2 mutation confirmed the diagnosis of LDS. Losartan was started for vascular protection. Conclusions: LDS is a severe inherited vasculopathy that usually presents in childhood. It is characterized by aortic root dilatation and ascending aneurysms. There is a higher risk of aortic dissection compared with MFS. Clinical features overlap with MFS and Ehlers Danlos syndrome Type IV, but differentiating dysmorphogenic features include ocular hypertelorism, bifid uvula and cleft palate. Echocardiography and MRA or CT scanning from head to pelvis is recommended to establish the extent of vascular involvement. Management involves early surgical intervention, including early valve-sparing aortic root replacement, genetic counselling and close monitoring in pregnancy. Despite being caused by loss of function mutations in either TGF尾 receptor, paradoxical activation of TGF尾 signalling is seen, suggesting that TGF尾 antagonism may confer disease modifying effects similar to those observed in MFS. TGF尾 antagonism can be achieved with angiotensin antagonists, such as Losartan, which is able to delay aortic aneurysm development in preclinical models and in patients with MFS. Our case emphasizes the importance of timely recognition of vasculopathy syndromes in patients with hypermobility and the need for early surgical intervention. It also highlights their heterogeneity and the potential for late presentation. Disclosures: The authors have declared no conflicts of interes

    Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

    Get PDF
    Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

    The difficulty in diagnosing X linked adrenoleucodystrophy and the importance of identifying cerebral involvement

    No full text
    Two patients are described, a mother and son, who were initially clinically diagnosed with hereditary spastic paraparesis. This was rectified after very long chain fatty acid testing confirmed adrenomyeloneuropathy (AMN). The son's initial symptoms were characteristic of AMN (the commonest phenotype) but progressed to show symptoms of cerebral involvement. This evolution from non-cerebral to cerebral AMN is recognised in the medical literature and is increasingly important to consider in light of the availability of potential treatments such as haematopoietic stem cell transplantation.RD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted
    corecore